TY - JOUR
T1 - Mesenchymal stromal cell therapy for liver diseases
AU - Alfaifi, Mohammed
AU - Eom, Young Woo
AU - Newsome, Philip N.
AU - Baik, Soon Koo
PY - 2018/2
Y1 - 2018/2
N2 - The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.
AB - The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.
KW - mesenchymal stromal cell
KW - liver disease
KW - enrichment
KW - priming
KW - genetic engineering
UR - http://europepmc.org/abstract/med/29425678
U2 - 10.1016/j.jhep.2018.01.030
DO - 10.1016/j.jhep.2018.01.030
M3 - Article
C2 - 29425678
SN - 0168-8278
JO - Journal of Hepatology
JF - Journal of Hepatology
ER -